The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Multi-center analytical performance evaluation of the Access Hybritech® p2PSA immunoassay.
Lori J Sokoll; Daniel W Chan; George G Klee; William L Roberts; Ron H N van Schaik; Dorothy A Arockiasamy; Dennis L Broyles; Corey M Carlson; Isaac A Mizrahi; Tina B Pierson; et al. (Profiled Authors: Daniel Chan; Lori Sokoll)
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, United States.
Clinica chimica acta; international journal of clinical chemistry 2012;413(15-16):1279-83.
BACKGROUND: Total PSA assays measure both complexed and non-complexed forms of PSA while free PSA assays only measure non-complexed forms. Free PSA is a mixture of isoforms including immature PSA (proPSA) with retained portions of the leader sequence (e.g. [-7], [-4], and [-2]proPSA) and nicked forms (BPSA). ProPSA isoforms in male sera have been associated with prostate cancer. This study characterized the analytical performance of a chemiluminescent immunoassay for [-2]proPSA. METHODS: The Access Hybritech p2PSA assay is a sandwich immunoassay using an anti-[-2]proPSA monoclonal antibody attached to paramagnetic beads and an anti-PSA monoclonal antibody conjugated to alkaline phosphatase calibrated with recombinant [-2]proPSA. Analytical studies including sensitivity (CLSI EP17-A) and imprecision (CLSI EP5-A2) were performed. RESULTS: The Access Hybritech p2PSA assay for [-2]proPSA had a dynamic range of 0.5 to 5000 pg/ml. The total CV of the assay was <7% for [-2]proPSA concentrations between 20 and 1000 pg/ml. The LOB was 0.50 pg/ml, LOD 0.69 pg/ml, and LOQ 3.23 pg/ml (20% CV). There was no hook effect up to 15,000 pg/ml. There was a <5% difference between calibrator and reagent lots and no interference from normal serum constituents. CONCLUSIONS: The Access Hybritech p2PSA assay is a robust immunoassay for the measurement of serum [-2]proPSA.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Alexander Haese; Robert T Dworschack; Steven P Piccoli; Lori J Sokoll; Alan W Partin; Daniel W ChanClinical chemistry 2002;48(6 Pt 1):944-7.
R J Laffin; D W Chan; M J Tanasijevic; G A Fischer; W Markus; J Miller; P Matarrese; L J Sokoll; D J Bruzek; J Eneman; et al.Clinical chemistry 2001;47(1):129-32.
W Uhl; D W Chan; K Jones; C Kelley; G Assmann; A von Eckardstein; A Sägers; J P Yvert; A M Schneider; A Torralba; et al.Wiener klinische Wochenschrift 1998;110 Suppl 3():51-61.
Appears in this Publication
Author of this Publication